AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee.

Krown, Susan E.; Testa, Marcia A.; Huang, Jie

doi:10.1200/jco.1997.15.9.3085

Cited by 256 publications

(145 citation statements)

References 0 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Patients with other neoplasms and those with HHV-8 disease diagnosed before January 1996 were not eligible for the study. The following epidemiological and clinical data were recorded at the time of KS diagnosis (baseline): age, gender, HIV risk group, known duration of HIV infection, the ACTG stage of KS (Krown et al, 1997), specific chemotherapy for KS, and associated multicentric Castleman disease. Central, east, west Africa, southern Italy and south America were considered as endemic countries for HHV-8 infection.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

et al. 2006

View full text Add to dashboard Cite

Highly active antiretroviral therapy (HAART) reduces the incidence and improves the prognosis of Kaposi's sarcoma (KS). This study was designed to identify factors associated with KS clinical responses in HIV-infected patients during HAART. We reviewed the files of 138 HIV-1-infected patients with KS. Epidemiologic and HIV-related clinical and biological parameters were recorded at KS diagnosis (baseline) and every 6 months thereafter. In a subset of 73 antiretroviral-naive patients, we compared the clinical outcome of KS according to the use or nonuse of protease inhibitors (PI). After 6 months of follow-up, KS remission was more frequent in patients who were naive of HAART and who were at ACTG stage S0 at baseline (P ¼ 0.03 and 0.02). Undetectable HIV viral load was strongly associated with KS remission (Pp0.004 at all time points), while CD4 cell count was not. Among the 73 antiretroviralnaive patients at baseline, and who were studied for 24 months, KS outcome did not differ between patients who were prescribed PIcontaining and PI-sparing regimens. Intercurrent multicentric Castleman's disease was associated with poor outcome after 60 months of follow-up (Pp0.0001). Fourteen deaths occurred after a median follow-up of 37.5 months, eight of which were KS related. Suppression of HIV replication appears to be crucial to control KS. Non-PI-based regimens were equivalent to PI-based regimens as regards the clinical and virological outcome of antiretroviral-naive HIV-infected patients with KS.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The choice of HAART was left to the patients' individual physicians. 'KS remission' refers to partial or complete remission as defined in ACTG study (Krown et al, 1997), and 'KS progression' refers to stable disease, progressive lesions or death related to KS.…”

Section: Methodsmentioning

confidence: 99%

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The AIDS clinical trial group staging classification is used to stage KS and takes into account the extent of tumour, immune status and severity of systemic illness [16][17][18] (Table I). This score was developed before the HAART era and now with patients on antiretroviral therapy, the systemic and tumour scores are more useful as prognostic indicators than the CD4 count [18].…”

Section: Stagementioning

confidence: 99%

The management of children with Kaposi sarcoma in resource limited settings

Molyneux

Davidson

Orem

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is common where HIV infection is endemic. Antiretroviral therapy (ART) has reduced the incidence in well‐resourced settings but in some parts of the world access to ART is delayed. These recommendations are for use where only minimal requirements for treatment are available. Consensus was sought for the management of childhood HIV‐associated KS in this setting. There are no randomised controlled studies of chemotherapy for KS in children and these recommendations have drawn on consensus of a group of experts and published reports from studies in adults. Pediatr Blood Cancer 2013; 60: 538–542. © 2012 Wiley Periodicals, Inc.

show abstract

“…Patients with T0-, I0-, and S0-stage diseases have confined lesions, CD4 T-cell counts above 200, and good performance status without opportunistic infections, respectively (13). Individuals with T1 (disseminated KS)-, I1 (low CD4 T-cell counts)-, and S1 (opportunistic infections and/or poor performance status)-stage diseases have worse disease outcomes (13). We investigated the relationship between KS disease stage and the proportion of NKG2C ϩ cells in our AIDS KS patients.…”

mentioning

confidence: 99%

“…Patients tumor, immune system, and systemic illness staging system (13). Peripheral blood mononuclear cells were prepared from venous blood by standard Ficoll-Hypaque separation.…”

mentioning

confidence: 99%

NKG2C ⁺ NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma

Goodier

Mela

Steel³

et al. 2007

J Virol

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is an AIDS-defining condition in individuals withRecognition of infected target cells by NK cells is regulated by receptors for major histocompatibility complex class I (MHC-I) and pathogen-derived molecules (3,14). Killer cell immunoglobulin-like receptor (KIR) family members, which are expressed on NK cells, influence the risk of progression to AIDS in combination with HLA-B alleles (15, 16). However, the proportion of NK cells expressing inhibitory KIR increases and those expressing activating natural cytotoxicity receptors (NCR) are less abundant in PWHA (1,5,6,17).We have shown that NK cells from PWHA are enriched for a subset bearing the C-type, lectin-like receptor NKG2C (20). The NKG2C receptor mediates NK cell responses to a limited set of ligands in association with HLA-E, including a human cytomegalovirus (HCMV) peptide, and to HCMV-infected fibroblasts (9, 10). However, NK cells bearing NKG2C predominantly express inhibitory KIR and have low levels of activating NCR, which may compromise their abilities to mount cytolytic responses (8,20).As NKG2C ϩ NK cells have a predominantly inhibitory phenotype, the dominance of this subset could have an impact on disease prognosis in AIDS patients, including those with KS. We used the AIDS Clinical Trial Group (ACTG) clinical staging system, which is applied to all AIDS KS patients upon diagnosis, to investigate the relationship between the NK cell phenotype and function and disease prognosis in HIV-1 infection.Patients

show abstract

AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee.

Abstract: The ACTG TIS classification predicts survival in patients with AIDS-associated KS; CD4 count and tumor stage provide the most predictive information. However, a lower CD4 count than the one originally proposed provides better discrimination between prognostic groups.

Cited by 256 publications

References 0 publications

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

The management of children with Kaposi sarcoma in resource limited settings

NKG2C ⁺ NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma

Contact Info

Product

Resources

About

AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee.

Abstract: The ACTG TIS classification predicts survival in patients with AIDS-associated KS; CD4 count and tumor stage provide the most predictive information. However, a lower CD4 count than the one originally proposed provides better discrimination between prognostic groups.

Cited by 256 publications

References 0 publications

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy

The management of children with Kaposi sarcoma in resource limited settings

NKG2C + NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma

Contact Info

Product

Resources

About

NKG2C ⁺ NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma